Search Results 491-500 of 18365 for alopecia
Has not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to randomization (excluding alopecia, ...
prior therapies (excluding alopecia, neuropathy, and nail changes). - Clinical laboratory values as specified below within 14 days before the first dose of
alopecia or peripheral neuropathy, or if controlled on thyroid replacement therapy). - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ...
Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) ...
Recovered from prior chemotherapy (i.e., toxicities ≤ grade 1 [except for neuropathy and alopecia]); Thoracic radiotherapy administered concurrently with or ...
Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment; - Conditions not expected to recur in the absence of an external ...
Exception: alopecia. Current use of prohibited medication: Concomitant administration of potent CYP3A4 inhibitors and inducers and moderate CYP3A4 inducers ...
0) with the exception of which inclusion criteria allowed, alopecia, vitiligo and neurotoxicity Grade ≤2 that investigator believe don't affect safety ...
Recovery from adverse effects of prior therapy at time of enrollment to o ≤ Grade 1 (excluding alopecia); Agreement to forego any other chemotherapy ...
Presence of a drug-related toxicity from prior cancer therapy that has not resolved to Grade ≤1 (with the exception of alopecia and Grade 2 neuropathy) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!